After serving two years at Grifols Innovation and New Technologies, Gasol Escuer has accepted a new position at global venture firm AdBio Partners
Emma Gasol Escuer departed from Grifols Innovation and New Technologies, the corporate venture arm of Spain-based pharmaceutical corporation Grifols.
After two years as director of innovation scouting at Grifols External Innovation and Corporate Venturing unit, Gasol Escuer has joined venture capital firm AdBio Partners as investment director.
Her new role will involve Gasol Escuer identifying and conducting investments across Europe while overseeing AdBio Partners’ existing portfolio.
An experienced pharmaceutical investor, Gasol Escuer previously spent three years as a director of corporate development at Laboratorios Gebro Pharma, a Barcelona-headquartered pharmaceutical manufacturer, before joining Grifols.
Founded in 2015, Grifols Innovation and New Technologies invests in startups developing patient therapeutics, new drugs and biopharmaceuticals. The unit’s portfolio companies include cardiology and oncology cell therapy treatment developer Celyad.
“I am delighted and grateful to have the opportunity to join AdBio Partners as investment director to invest in new treatments for patients with high unmet clinical needs,” said Gasol Escuer in a statement.
”I am looking forward to contributing to AdBio Partners’ development in Europe as I strongly believe that early-stage investment is the first and most important step to accelerate the translation of academic innovation into the clinic.”
